An observational study in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Indonesia. Per ClinicalTrials.gov, last updated 2017-02-28.
Sponsored by Novo Nordisk A/S · Observational
This study is conducted in Asia. The aim of this study is to investigate the safety and efficacy of NovoLet® human insulin delivery system in an outpatient setting.
11,090 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 1,981 is above the median of 234 across 2,254 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Novo Nordisk A/S is the lead sponsor of 1,401 studies on the registry; 102 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 98 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with type 1 or type 2 diabetes mellitus or other types of diabetes mellitus (gestational, drug induced or metabolic syndrome-related) who are prescribed NovoLet® human insulin in the course of their diabetes mellitus management can be enrolled in the study
Inclusion Criteria:
Drug: biphasic human insulin · Drug: isophane human insulin · Drug: human soluble insulin
Drug pages: Insulin, Regular, Human · Insulin, Isophane
NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Change in body weight
Fasting blood glucose (FBG)
2 hours postprandial blood glucose (2-hr PPBG)
HbA1c (glycosylated haemoglobin)
Adverse events (AEs) including hypoglycaemic episodes
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.